Immune Heterogeneity Before and After Cardiopulmonary Bypass in Children

Zhejiang University

Status: Completed

Conditions: Ventricular Septal Defect

Study type: Observational

Funder types: Other

Identifiers

NCT06214182

2023-IRB-0303-P-01

Details and patient eligibility

About

The goal of this observational study is to learn about functional heterogeneity of immune cells before and after cardiopulmonary bypass (CPB) in children with congenital heart disease (CHD). The main question[s] it aims to answer are:

• Does CPB cause immune paralysis after CHD surgery?
• How does the functional heterogeneity of immune cells change before and after CPB in children undergoing CHD surgery? Participants will receive 3ml of peripheral blood before CPB, 2 hours after CPB, and 3 days after CPB, and the peripheral blood samples will be sequenced by single cell to explore the immune heterogeneity before and after CPB.

Full description

CPB-induced immune paralysis is the main cause of postoperative infection in CHD, which seriously affects the prognosis of children. The underlying mechanism of CPB-induced immune paralysis has not been fully determined. This study intends to use scRNA-seq to describe gene transcription profiles of immune cells in peripheral blood of children undergoing CHD surgery before and after CPB, and explore the differences within and between different immune cell populations including T cells and the changes of immune cells in different sequences. To fill the gap in the study of immune mechanism in CPB-induced immune paralysis microenvironment at single-cell resolution.

Enrollment: 3 patients

Sex: All

Ages: 31 days to 1 year old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Birth weight range: 2500-6000g;
2. Operation duration >90min;

Exclusion criteria

1. preterm infants or preoperative infections;
2. systemic immune diseases and serious complications: such as rheumatoid arthritis, systemic lupus erythematosus, severe liver and kidney function damage, leukemia, etc.;
3. Patients who have received an organ transplant;
4. Patients who have received immunomodulatory drugs: patients who have received immunomodulatory drugs before surgery;
5. Parents refused to participate or were unable to provide sufficient samples: Parents or legal guardians refused to participate in the study.

Trial design

3 participants in 3 patient groups

Group T1

Description:

T1 is before CPB.

Group T2

Description:

T2 is 2 hours after CPB.

Group T3

Description:

T3 is 3 days after CPB.